Astec LifeSciences Limited — Updates, 25-10-2024: Press Release

Astec LifeSciences Limited reported its unaudited financial results for Q2 FY25, revealing a consolidated total income of ₹100.5 crore, down 10.1% from ₹111.8 crore in Q2 FY24. The company faced a consolidated EBITDA loss of ₹17.7 crore, compared to a loss of ₹2.4 crore a year prior. For H1 FY25, total income dropped 33.4% to ₹170.8 crore, with an EBITDA loss of ₹63.1 crore versus a profit in H1 FY24, primarily due to lower product realizations and cautious customer behavior.